Pancreatosteatosis in patients with adrenal incidentaloma: A risk factor for impaired glucose metabolism

Candemir B., Kisip K., Akın Ş., Tuba Sanal H., Taşar M., ALTUNKAYNAK B., ...Daha Fazla

Diabetes Research and Clinical Practice, cilt.208, 2024 (SCI-Expanded) identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 208
  • Basım Tarihi: 2024
  • Doi Numarası: 10.1016/j.diabres.2024.111099
  • Dergi Adı: Diabetes Research and Clinical Practice
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, BIOSIS, CAB Abstracts, CINAHL, EMBASE, Index Islamicus, MEDLINE, Veterinary Science Database
  • Anahtar Kelimeler: Adrenal incidentaloma, Computed tomography, Diabetes mellitus, Dysglycemia, Glucose metabolism, Pancreatosteatosis
  • Gazi Üniversitesi Adresli: Evet

Özet

Aims: Patients with adrenal incidentaloma (AI) are at increased risk of impaired glucose metabolism, which is known to be associated with pancreatosteatosis (PS). We aimed to investigate the risk of developing dysglycemia for patients with non-functioning AI (NFAI) versus those without, and whether the presence of PS predicts future dysglycemia in patients with NFAI. Method: In 80 patients with NFAI and 127 controls matched for age, sex, and body mass index, changes in fasting plasma glucose (FPG) and hemoglobin A1c(HbA1c) were evaluated at 2 years. PS was evaluated with data obtained from non-contrast abdominal computed tomography (CT) performed at the initial evaluation. Results: Mean FPG levels increased significantly after 2 years in both groups (P < 0.001, for both), albeit significantly higher among patients than the controls (P = 0.002). The increases in HbA1c and FPG levels were significantly higher among patients with PS than without PS, in the adenoma group (p < 0.001, P = 0.00, respectively). The change in Hba1c levels was associated with the presence of PS in patients with NFAI (p < 0.001). Conclusions: Our findings suggest that the presence of PS may provide significant information in predicting newly developed dysglycemia in patients with NFAI.